VivoSeq
Infectious Disease

Coronavirus Infectious Disease

10

Pipeline Programs

0

Active Trials

6

Companies Involved

Coronavirus Infectious Disease is an early-stage landscape with 10 programs across 6 companies. The most active players are Altimmune, Alnylam Pharmaceuticals, AbbVie. 7 therapies are approved.

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

22/100

Completion Rate

0/100

Attrition Rate

100/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Trial Status

1

clinical trials

Terminated1 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)